A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging.

BACKGROUND Traditional statistical analysis of 2 surgeons' experiences with resectable malignant melanoma during a 30-year period (November 1970-July 2000) was compared with new tree-structured recursive partitioning regression analysis. METHODS A total of 1018 consecutive patients were registered and 983 patients were evaluable. Disease-free survival (DFS) and melanoma survival (MS) were calculated by Kaplan-Meier method for stage, thickness, ulceration, site, lymph node involvement, age, sex, and type; and compared with log-rank tests. Cox proportional hazards model was used for multivariate analysis. Multivariate predictors were used to analyze DFS and MS with a classification and regression tree model that partitioned patients into progressively more homogenous prognostic groups with significantly different Kaplan-Meier curves. RESULTS Multivariate correlations were with thickness (millimeters), ulceration, age (per year), type, and sex in predicting DFS (relative risk = 1.18, 2.10, 1.05, 1.71, and 1.71, respectively). Thickness, ulceration, age, and type remained significant predictors of MS (relative risk = 1.14, 3.02, 1.02, and 2.30, respectively). Classification and regression tree analysis showed thickness, age, ulceration, and sex affected DFS. Only thickness and ulceration were significant in predicting MS. CONCLUSION The Cox model is an important tool for analysis of clinical data but has flaws. New statistical technology to predict outcome should be considered. Classification and regression tree analysis of larger published series may reveal new predictors useful for staging, prognosis, and guiding clinical decisions.

[1]  D L Morton,et al.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. , 1999, Annals of surgery.

[2]  Mark R. Segal,et al.  Regression Trees for Censored Data , 1988 .

[3]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. LeBlanc,et al.  Relative risk trees for censored survival data. , 1992, Biometrics.

[5]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[6]  M. Mihm,et al.  Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm) , 2000, Annals of Surgical Oncology.

[7]  Robert B. Shibuya,et al.  Stage I Renal Cell Carcinoma: A Clinicopathologic Study of 82 Cases , 1993, The American journal of surgical pathology.

[8]  M. Ross,et al.  Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy , 2001, Annals of Surgical Oncology.

[9]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[10]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[11]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J Halpern,et al.  27-year mortality in the Western Collaborative Group Study: construction of risk groups by recursive partitioning. , 1991, Journal of clinical epidemiology.

[13]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[14]  R. Olshen,et al.  Tree-structured survival analysis. , 1985, Cancer treatment reports.

[15]  M. Ross,et al.  Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed? , 2001, Annals of Surgical Oncology.

[16]  C W Cruse,et al.  Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. , 1996, Annals of surgery.

[17]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Reintgen,et al.  Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. , 1997, The Journal of the Florida Medical Association.

[19]  E. Mansour,et al.  A long-term analysis of 620 patients with malignant melanoma at a major referral center. , 1998, Surgery.

[20]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.